Psychiatry

Carrie Jardine and Martin Rosenzweig, MD, share considerations for benefit design in behavioral health.

There were key aspects that differed in the gut microbiota between patients with major depressive disorder and the healthy control group.

Palliative care programs were challenging during the COVID-19 pandemic.

Females were disproportionately affected by some of the restrictions put in place in the early stages of the COVID-19 pandemic.

Experts in behavioral health discuss overcoming barriers to access for alternative therapies for TRD, including the Risk Evaluation and Mitigation Strategy (REMS) requirement for intranasal esketamine.

Dr Patricia Ares-Romero and Dr Martin Rosenzweig discuss treatment strategies for TRD, including alternative therapies, and explain barriers within the health care system that inhibit access.

Patients with inflammatory bowel disease are at an increased risk of developing depression.

Drs Samuel Nordberg, Patricia Ares-Romero, and Martin Rosenzweig share considerations for effective care delivery for patients with TRD.

Experts in behavioral health discuss therapeutic options for TRD and considerations for defining value.

While it is known that ASD is linked to altered gut microbiota, there is little research into the altered bacterial species.

The digital software program was significantly beneficial and tolerable among patients who used it over 6 weeks, according to new findings.

Dr Samuel Nordberg and Carrie Jardine discuss barriers to accessing care for patients with TRD and provide insight on addressing these concerns to achieve optimal care.

Dave Bellevue of The Oxymorrons joins Steve to talk about his journey to mental health advocacy.

There is a need for new medications for depression to overcome high rates of treatment resistance.

Dr Samuel Nordberg discusses methods for identifying patients in need of an alternative therapy for TRD at the health system level.

The treatment represents the only FDA approved orally dissolving sublingual film for this patient population.

Patricia Ares-Romero, MD, reviews the frequency of TRD diagnosis and common risk factors, and Martin Rosenzweig, MD, explores patient identification and economic burden of disease.

Samuel Nordberg, PhD, discusses challenges with the definition and identification of TRD in the clinical setting.

Human milk oligosaccharides could help treat some of the gut disruptions patients with depression often have.

Subhdeep Virk, MBBS, chaired the recent State of the Science event on treatment-resistant depression.

Case-control analyses suggest older patients may cognitively age by about 8 years within 6 months of being discharged for severe COVID-19.

Cross-sectional analysis of national survey data suggest students with multiple marginalized identities are more prone to treatment that could lead to burnout.

The use and legalization of cannabis products has been increasing in the US for a variety of medical concerns. Investigators aim to better understand the risks and benefits of owning a medical marijuana card.

The hope is society learns some of the lessons from the Cold War to better help patients with mental health concerns.